Dallah Healthcare Co. announces its Interim Financial Results for the Period Ending on 2020-03-31 ( Three Months )
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 314.6 | 321.1 | -2.024 | 343.6 | -8.44 |
| Gross Profit (Loss) | 105.8 | 120.3 | -12.053 | 127.3 | -16.889 |
| Operational Profit (Loss) | 26.4 | 41.2 | -35.922 | 64.1 | -58.814 |
| Net Profit (Loss) after Zakat and Tax | 19.2 | 35.2 | -45.454 | 69.8 | -72.492 |
| Total Comprehensive Income | 19.2 | 35.1 | -45.299 | 69.3 | -72.294 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Total Share Holders Equity (after Deducting Minority Equity) | 1,491.5 | 1,522.1 | -2.01 |
| Profit (Loss) per Share | 0.27 | 0.47 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| Increase (Decrease) in Net Profit for Current Quarter Compared to the Same Quarter of the Previous Year is Attributed to | Decrease in net profit for the current quarter compared to the same quarter of the last year is due to:
1- Recession in number of patients due to MoH instructions about the proactive application of infection control, and the preventive precautions as part of the effective infections control policy the company is following. 2- Increase in credit loss provision compared to the same quarter of last year that were low due to settlement of claims by one of its costumers during the first quarter of 2019 that was already provided for earlier. 3- Increase in pre-operating expenses of Dr. Moahemd Alfaqeeh Hospital that the company owns a share in. This is while the Zakat expenses decrease as a result of decreasing Zakat base accordingly. |
| Increase (Decrease) in Net Profit for Current Quarter Compared to the Previous Quarter is Attributed to | Decrease in the net profit for this quarter compared to last quarter is due to:
1- Recession in number of patients due to MoH instructions about the proactive application of infection control, and the preventive precautions as part of the effective infections control policy the company is following. 2- Posting of gains in revaluation of investment fund during the fourth quarter which is usually performed at the year end. |
| Basis of the External Auditor's Opinion | Unmodified opinion |
| Reclassification of Comparison Items | Elements and notes of the comparatives Interim Condensed Consolidated Financial Statements have been reclassified and regrouped to meet with the International Financial Reporting Standards (IFRS) that are endorsed in the Kingdom of Saudi Arabia. During the current quarter, there has been remeasurement of some estimations and judgements that the company is basing on in it the process accompanying the preparing the interim financial statements as a result of Coronavirus (COVID-19). For more info, please refer to Note 14 (The effect of Coronavirus (COVID-19) on the condensed consolidated financial statements) in the notes accompanying the financial statements for the period ended 31 March 2020. |
| Additional Information | Earnings-per-share is calculated based on the weighted average number of standing shares amounted to 71,260,000 shares for the three months ended 31 March 2020 (compared to 74,950,013 shares for the three months ended 31 March 2019)
The company issued 16 million shares according to the EGM’s approval in 26/2/2019 on increasing the company’s capital through distribution of free shares with a ratio of 27.1% to increase the number of outstanding shares from 59 million to 75 million shares.
We would like to draw the attention to the shareholders that the interim condensed consolidated financial statements for the first quarter ended 31 March 2020 will be available through the following link on the company 's Website after submitting them to the related authorities. http://www.dallahhealth.com/english/investors
The company would like also to draw the attention of the financial analysts and investors to send their inquiries to the company’s email: ir@dallahhealth.com during 10 days from publishing of the financial |
Comments